After excluding patients with unknown mismatch repair (MMR) status (n=39) or unknown RAS or BRAF mutational status (n=72), 2236 colorectal cancer (CRC) patients were available for analyses (Fig. 1). This evidence concerns the gene BRAF and colorectal carcinoma.